Time-course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow

Journal of Applied Clinical Medical Physics

Volumn 9, Issue 3, 2008, Pages 147-156

  Kesner, Adam L ^a   Lau, Victoria K ^a   Speiser, Michael ^a   Hsueh, Wei Ann ^a   Agazaryan, Nzhde ^a   DeMarco, John J ^a   Czernin, Johannes ^a   Silverman, Daniel H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FDG; Radiation therapy; Small animal PET; Treatment monitoring

Indexed keywords

EID: 57049111471     PISSN: None     EISSN: 15269914     Source Type: Journal    
DOI: 10.1120/jacmp.v9i3.2747     Document Type: Article

References (46)

1. Juweid ME. Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354(5):496-507.
2. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007;48 Suppl 1:S78-88.
3. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med. 2004;45 Suppl 1:S4-14.
4. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22(6):3255-3260.
5. Bender H, Bangard N, Metten N, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma. 1999;18(1):87-91.
6. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24(2):127-135.
7. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14(3):700-708.
8. Kostakoglu L, Coleman M, Leonard.TP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43(8):1018-1027.
9. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21(24):4604-4610.
10. Romer W, Hanauske AR, Ziegler S, et al, Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91(12):4464-4471,
11. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]Fluorodeoxyglacose for monitoring primary chemotherapy in breast cancer, J Clin Oncol. 2000; 18(8):1689-1695.
12. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000; 18(8):1676-1688.
13. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002; 13(9):1356-1363.
14. Wahl RL, Zasadny K. Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993; 11(11):2101-2111.
15. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19(12):3058-3065.
16. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21(14):2651-2657.
17. Hautzel H, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med. 1997;38(9):1384-1386.
18. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging. 2006; 33 Suppl 1: S27-37.
19. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007;37(3):206-222.
20. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23(10):1409-1415,
21. Higashi T, Fisher SJ, Brown RS, Nakada K, Walter GL, Wahl RL. Evaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: preclinical PET studies. J Nucl Med. 2000;41(12):2026-2035.
22. Udagawa T. Birsner AF. Wood M, D'Amato RJ. Chronic suppression of angiogenesis following radiation exposure is independent of hematopoietic reconstitution. Cancer Res. 2007;67(5):2040-2045.
23. Laing EJ, Fitzpatrick PJ, Norris AM, et al. Half-body radiotherapy. Evaluation of the technique in normal dogs. J Vet Intern Med. 1989;3(2):96-101.
24. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol. 2003;62(6):593-604.
25. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol. 2007;28(1):12-18.
26. Engelhardt B. Regulation of immune cell entry into the central nervous system. Results Probl Cell Differ. 2006;43:259-280.
27. van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45(4):695-700.
28. International Commission on Radiological Protection (ICRP). Radiation dose to patients from radiopharmaceuticals. Publication no. 53. Oxford (UK): Pergamon Press;1987. p.75.
29. Molla M, Panes J. Radiation-induced intestinal inflammation. World J Gastroenterol. 2007;13(22):3043-3046.
30. Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 1996;56(22):5150-5155.
31. Rube CE, Uthe D, Wilfert F, et al. The bronchiolar epithelium as a prominent source of pro-inflammatory cytokines after lung irradiation. Inf J Radiat Oncol Biol Phys. 2005;61(5):1482-1492,
32. Agrawal A, Choudhary D, Upreti M, Rath PC, Kale RK. Radiation induced oxidative stress: I. Studies in Ehrlich solid tumor in mice. Mol Cell Biochem. 2001;223(1-2):71-80.
33. Engenhart R, Kimmig BN, Strauss LG, et al. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Strahlenther Onkol. 1992; 168(4):203-212.
34. Ohtsuka T, Nomori H, Watanabe K, et al. False-positive findings on [18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer. Jpn J Clin Oncol. 2005;35(5):271-273.
35. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35(1):104-112.
36. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33(11):1972-1980.
37. Shiraki N, Hara M, Ogino H, et al. False-positive and true-negative hilar and mediastinal lymph nodes on FDG-PET - radiological-pathological correlation. Ann Nucl Med. 2004:18(1):23-28.
38. Nishikawa A, Furukawa F, Imazawa T, et al. Cell proliferation in lung fibrosis-associated hyperplastic lesions. Hum Exp Toxicol. 1995;14(9):701-705.
39. astellucci P, Zinzani P, Nanni C, et al. 18F-FDG PET early after radiotherapy in lymphoma patients. Cancer Biother Radiopharm. 2004;19(5):606-612.
40. International Commission on Radiological Protection (ICRP). Radiological Protection in Biomedical Research. Publication no. 62. Oxford (UK): Pergamon Press, 1993. p.9-10.
41. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology. 1995;196(1):167-173.
42. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40(11):1771-1777.
43. Kong FM, Frey KA, Quint LE, et al, A pilot study of [18F]fluorodeoxyglucose positron emission (tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol. 2007i25(21):3116-3123.
44. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol. 2007;82(2):145-152.
45. Wong CY, Thie J, Gaskill M, et al. Addressing glucose sensitivity measured by F-18 FDG PET in lung cancers for radiation treatment planning and monitoring. Int J Radiat Oncol Biol Phys. 2006;65(1):132-137.
46. Kubota K, Ishiwata K, Kubota R, et al. Tracer feasibilitv for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J Nucl Med. 1991;32(11):2118-2123.